Previous 10 | Next 10 |
FLORHAM PARK, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the...
Interest in Cellectar Biosciences (CLRB) from private equity firms this week jumped this week as evidenced by several SEC Form 13G and Form 13G/A amended filings.This week, Consonance Capital Management and Sio Capital Management both filed Form 13G.Consonance's filing lists 4,...
FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, presid...
Analysts Say These Are Penny Stocks To Buy; Do You Agree? We talk a lot about penny stocks for obvious reasons. But do you know how to find the right stocks to buy? I’m sure that if you’re like most in the stock market today, you’re searching for volatility. We ...
The EMA has adopted a positive opinion for Cellectar Biosciences' (CLRB) CLR 131 orphan designation for the treatment of Waldenstrom’s Macroglobulinemia ((WM)). Cellectar has initiated a pivotal trial evaluating CLR 131 in WM patients that have failed or had a suboptimal response to a ...
FLORHAM PARK, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the European Medicin...
Cellectar Biosciences ([[CLRB]] +4.3%) has initiated a pivotal trial in the U.S., for CLR 131 in Waldenstrom’s macroglobulinemia ((WM)), a rare cancer of the bone marrow and lymphatic tissues.The pivotal trial is designed as a global, non-comparator, single arm, expansion cohort of the...
FLORHAM PARK, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced the initiation of a pivot...
Insiders Made These Their Top Penny Stocks To Buy Before The New Year Whether we’re talking about penny stocks or blue-chip stocks, insider transactions are always something of interest for traders. Playing more to the psychology of day trading or investing, when insiders...
FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously a...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
17.22%Change Percent:
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...